SPOTLIGHT: Low Avastin price for Japan

Japanese regulators have set a price on Avastin that's 40 percent lower than in the U.S., marking stiffening opposition to high cancer drug prices. Shares of Chugai slid on the news. Report

Suggested Articles

Merck’s TIGIT-blocking prospect and PD-1 med Keytruda shrank tumors in 29% of lung cancer patients who had never tried a checkpoint inhibitor.

Merck's HIF-2α inhibitor, picked up in its $1 billion Peloton buyout, shrank kidney tumors in 36% of patients and showed promise in other tumors, too.

Amunix reported that a single dose of its lead T-cell engager caused caused large HER2-positive tumors to shrink in mice.